Pfizer Inc (PFE)
Receivables turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 63,627,000 | 60,113,000 | 55,643,000 | 55,094,000 | 58,497,000 | 68,538,000 | 77,944,000 | 92,952,000 | 100,331,000 | 99,879,000 | 101,335,000 | 92,570,000 | 81,491,000 | 69,337,000 | 57,374,000 | 50,198,000 | 47,644,000 | 48,648,000 | 49,197,000 | 50,660,000 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $63,627,000K ÷ $—K
= —
The receivables turnover ratio for Pfizer Inc is not available for the periods provided in the data. The receivables turnover ratio indicates how efficiently a company is able to collect outstanding receivables from its customers. It is calculated by dividing the net credit sales by the average accounts receivable balance.
Given that the receivables turnover data is not provided, it is not possible to assess how quickly Pfizer Inc is converting its receivables into cash during the periods mentioned in the data. A higher receivables turnover ratio generally indicates that a company has efficient credit and collection policies in place.
Without specific data on this ratio for Pfizer Inc, it is challenging to provide a detailed analysis of the company's effectiveness in managing its accounts receivable. Monitoring changes in the receivables turnover ratio over time can give insights into the company's liquidity, credit risk, and overall financial health.
Peer comparison
Dec 31, 2024